IMMUCELL CORP /DE/ 8K

ImmuCell Corporation reported improved quarterly revenues and profitability, aided by a $2 million legal settlement, and announced an approximately $8 million, 18‑month capacity expansion for its First Defense® product line.

ImmuCell Corporation filed a Form 8-K to furnish a press release announcing its unaudited financial results for the quarter ended June 30, 2026, reporting 11.5% year-over-year product sales growth to $7.2 million, net income of $1.8 million (including a one-time $2 million legal settlement from a former Re-Tain® contract manufacturer), a gross margin decline to approximately 34% due to lower manufacturing volumes and manufacturing headwinds, and adjusted EBITDA of $2.7 million, while also outlining a two-phase First Defense® capacity expansion program totaling about $8.0 million in freeze-drying and colostrum processing investments expected to be funded with cash on hand and cash from operations and completed over roughly 18 months.

Filing Facts

CIK

811641

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-027667

Alert Tier

6